Lilly Widens Obesity Lead as Novo Pipeline Stumbles
Get the Finance newsletter
Daily finance — markets, central banks, M&A, the prints that move money. Free.
- Eli Lilly held a 60.9% share of the U.S. obesity and diabetes drug market in Q2 versus Novo Nordisk's 38.8%, per Lilly's earnings presentation, with analysts calling a global incretin market potentially worth more than $100 billion by the 2030s.
- Eli Lilly posted 48% year-over-year revenue growth fueled by Mounjaro and Zepbound and hiked its full-year revenue guidance, reinforcing investor confidence despite lower U.S. pricing.
- Novo Nordisk's Wegovy pill revenue came in slightly below analyst expectations despite reaching more than 5 million patients since its January U.S. launch; CEO Mike Doustdar said the pill will enter Germany in September as its first EU market.
- Novo Nordisk's experimental obesity drug CagriSema failed to deliver as much blood sugar control as Zepbound in a large trial — the second time this year the drug has trailed Lilly's blockbuster.
- Novo Nordisk's late-stage experimental heart drug ziltivekimab failed to reduce major cardiovascular events compared to placebo, according to recent trial results.
- Analysts at BMO, Jefferies, Bernstein, and Citi said Novo's quarterly beat left questions about its 2027 growth path and the need for further pipeline diversification, with Citi summing it up as "nothing to inspire."
Why it matters: The U.S. obesity and diabetes drug market is now effectively a 60.9%-to-38.8% split favoring Lilly, and Novo's two separate pipeline trial failures — CagriSema and ziltivekimab — alongside a Wegovy pill that underwhelmed Wall Street leave the Danish drugmaker needing a convincing diversification story to keep pace. Novo's updated outlook implies a possible full-year sales decline, a stark contrast to Lilly's ballooning revenue trajectory.
